Announcements Trials
Browse Landscape

Phase

Phase 2 33Phase 1 11Phase 1/2 8Phase 3 6Phase NA 2Phase 2/3 2Phase EARLY_PHASE1 1Phase 4 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 2NET 1

Conditions

Neuroendocrine Tumors 1Advanced Neuroendocrine Neoplasm 1

Interventions

Cisplatin 98Gemcitabine 66Paclitaxel 62Carboplatin 60Fluorouracil 59Docetaxel 59Capecitabine 59Oxaliplatin 56Cyclophosphamide 54Radiotherapy 50Drug Therapy 46Bevacizumab 38pembrolizumab 35Dexamethasone 33Magnetic Resonance Spectroscopy 32Leucovorin 32Doxorubicin 31Cytarabine 27Etoposide 26Pemetrexed 25Nivolumab 24Methotrexate 24Radiation 20Vincristine 18venetoclax 17apatinib 17Rituximab 17Prednisone 17Letrozole 17Irinotecan 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × lutetium Lu 177 dotatate × Clear all
NCT06398444 2025-09-05

A Clinical Study of Lutetium[177Lu] Oxodotreotide Injection in Patients With Advanced Neuroendocrine Neoplasms

Sinotau Pharmaceutical Group

Phase 2/3 Active not recruiting
74 enrolled
Endocrine

Advanced Neuroendocrine Neoplasm

NCT03590119 2022-11-08

LUTIA

UMC Utrecht

Phase 2/3 Completed
26 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡